PAREXEL International’s peri-approval group PACE™, supports clients with strategies and systems specifically developed for Phase IIIb studies. PACE has an impressive record of conducting Phase IIIb studies of all sizes. Experience spans many therapeutic areas and ranges from single-country studies to those carried across multiple national boundaries and continents. In the past three years alone, PACE has conducted over 120 Phase IIIb clinical trials, treating more than 120,000 patients, at over 17,000 investigator sites worldwide. Recently conducted Phase IIIb trials include a 33,000 patient oncology trial conducted at over 2,900 sites in 29 countries and a 7,600 patient cardiovascular trial conducted at over 550 sites in over 30 countries worldwide.
Whether you need to position a product through comparative studies, develop line extensions or extend label claims, PACE can help expedite Phase IIIb studies from planning to execution by offering:
- A strategic approach to the design of Phase IIIb protocols
- Access to unique populations
- Innovative and cost-effective solutions to achieve critical endpoints relevant to Phase IIIb
- Experienced teams to support timely implementation and completion of Phase IIIb studies across the world
- Reliable feasibility assessments through long-established network of physicians
- Flexibility to supplement or complete ongoing trials
In an era in which considerable financial resources are at stake, PACE’s broad range of peri-approval services can help sponsors extend their product lifecycle, expand prescribing communities, increase product exposure and maximize return on investment by bridging drug development and commercialization.
For more information contact the PACE Group.